Interim Data From Imago BioSciences’ Phase 2b Study of Bomedemstat (IMG-7289) for Treatment of Myelofibrosis to Be Presented at 62nd American Society of Hematology Annual Meeting

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– #ASH20–Interim Data from Imago BioSciences’ Phase 2b Study of Bomedemstat for Treatment of Myelofibrosis to be Presented at ASH 2020 Annual Meeting